Despite the challenges posed by the ongoing conflict, Ukraine’s healthcare sector demonstrates remarkable resilience and adaptability. The country’s efforts to maintain and enhance its healthcare and research infrastructure are also keeping clinical trials on schedule. As we discussed in this article on Linkedin, over the past few decades, Ukraine has established itself as a strong option
I enjoy working as CRO and Trial Acceleration company in the highly challenging setting of Intensive Care – as agile, committed smaller companies we can show we make a difference and large CRO fail on the need to be fast and flexible. I attended this 43rd meeting of ISICEM to keep up in sepsis, more
Client 4SC AG: The Marketing Authorisation Application for resminostat has been accepted by the EMA as sufficient for examination. “Germany, 1 March 2024 – 4SC AG a biotech company improving the lives of patients suffering with advanced-stage cutaneous T-cell lymphoma (CTCL), announced today that that its MAA has been accepted by the EMA as sufficient
